Cocrystalline DHEA Formulations

Anders L. Berkenstam; Edward Kuczynski,; S Andersson, Alf; Jan-Ake Gustafsson; Carly S. Filgueira

Cocrystalline DHEA Formulations

Anders L. Berkenstam (Inventor), Edward Kuczynski, (Inventor), S Andersson, Alf (Inventor), Jan-Ake Gustafsson (Inventor), Carly S. Filgueira (Inventor)

Research output: Patent

Abstract

A cocrystalline DHEA composition with at least one additional coformer is disclosed for therapeutic formulations. The cocrystalline DHEA/coformer formulation including at least one coformer chosen from the group consisting of glutaric acid, maleic acid, tartaric acid, fructose, and wherein the L-isomer of tartaric acid and the D-isomer of fructose are utilized. The cocrystalline DHEA/coformer formulations include certain excipients as a solubilizer or inhibitor.

Original language	English (US)
Patent number	US2014315833
IPC	C07C 49/ 727 A I
Priority date	4/21/14
State	Published - Oct 23 2014

Cite this

@misc{4b9a8cb3c4834b919180f54b6dd59b0f,

title = "Cocrystalline DHEA Formulations",

abstract = "A cocrystalline DHEA composition with at least one additional coformer is disclosed for therapeutic formulations. The cocrystalline DHEA/coformer formulation including at least one coformer chosen from the group consisting of glutaric acid, maleic acid, tartaric acid, fructose, and wherein the L-isomer of tartaric acid and the D-isomer of fructose are utilized. The cocrystalline DHEA/coformer formulations include certain excipients as a solubilizer or inhibitor.",

author = "Berkenstam, {Anders L.} and Edward Kuczynski, and {Andersson, Alf}, S and Jan-Ake Gustafsson and Filgueira, {Carly S.}",

year = "2014",

month = oct,

day = "23",

language = "English (US)",

type = "Patent",

note = "US2014315833; C07C 49/ 727 A I",

}

TY - PAT

T1 - Cocrystalline DHEA Formulations

AU - Berkenstam, Anders L.

AU - Kuczynski,, Edward

AU - Andersson, Alf, S

AU - Gustafsson, Jan-Ake

AU - Filgueira, Carly S.

PY - 2014/10/23

Y1 - 2014/10/23

N2 - A cocrystalline DHEA composition with at least one additional coformer is disclosed for therapeutic formulations. The cocrystalline DHEA/coformer formulation including at least one coformer chosen from the group consisting of glutaric acid, maleic acid, tartaric acid, fructose, and wherein the L-isomer of tartaric acid and the D-isomer of fructose are utilized. The cocrystalline DHEA/coformer formulations include certain excipients as a solubilizer or inhibitor.

AB - A cocrystalline DHEA composition with at least one additional coformer is disclosed for therapeutic formulations. The cocrystalline DHEA/coformer formulation including at least one coformer chosen from the group consisting of glutaric acid, maleic acid, tartaric acid, fructose, and wherein the L-isomer of tartaric acid and the D-isomer of fructose are utilized. The cocrystalline DHEA/coformer formulations include certain excipients as a solubilizer or inhibitor.

M3 - Patent

M1 - US2014315833

ER -

Cocrystalline DHEA Formulations

Abstract

Fingerprint

Cite this